Acer Therapeutics Inc. (NASDAQ:ACER – Get Rating) – Equities research analysts at HC Wainwright issued their Q2 2023 earnings per share (EPS) estimates for Acer Therapeutics in a research report issued to clients and investors on Tuesday, March 28th. HC Wainwright analyst V. Bernardino forecasts that the biopharmaceutical company will post earnings per share of ($0.26) for the quarter. HC Wainwright has a "Buy" rating and a $12.00 price objective on the stock. The consensus estimate for Acer Therapeutics' current full-year earnings is ($0.23) per share.
Get
Acer Therapeutics alerts:
Acer Therapeutics Stock Up 1.3 %
Acer Therapeutics stock opened at $0.76 on Wednesday. Acer Therapeutics has a 52 week low of $0.65 and a 52 week high of $4.56. The company has a market capitalization of $16.01 million, a price-to-earnings ratio of -0.53 and a beta of 0.65. The stock has a 50-day moving average price of $1.86 and a 200 day moving average price of $1.84.
Institutional Trading of Acer Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Nantahala Capital Management LLC boosted its stake in shares of Acer Therapeutics by 76.0% in the fourth quarter. Nantahala Capital Management LLC now owns 1,226,191 shares of the biopharmaceutical company's stock worth $3,078,000 after acquiring an additional 529,653 shares during the last quarter. Knott David M Jr acquired a new stake in shares of Acer Therapeutics in the fourth quarter worth approximately $351,000. Vanguard Group Inc. boosted its stake in shares of Acer Therapeutics by 55.5% in the first quarter. Vanguard Group Inc. now owns 278,215 shares of the biopharmaceutical company's stock worth $807,000 after acquiring an additional 99,335 shares during the last quarter. Meridian Wealth Management LLC acquired a new stake in shares of Acer Therapeutics in the fourth quarter worth approximately $180,000. Finally, Renaissance Technologies LLC boosted its stake in shares of Acer Therapeutics by 216.8% in the second quarter. Renaissance Technologies LLC now owns 69,700 shares of the biopharmaceutical company's stock worth $88,000 after acquiring an additional 47,700 shares during the last quarter. 27.96% of the stock is currently owned by hedge funds and other institutional investors.
About Acer Therapeutics
(Get Rating)
Acer Therapeutics, Inc is a pharmaceutical company. engages in acquisition, development and commercialization of therapies for medical needs. Its product pipeline includes ACER-001 Edsivo and ACER-2820. The Edsivo is a type of celiprolol for Vascular Ehlers-Danlos syndrome. The ACER-001 is for the treatment of urea cycle disorders and Maple Syrup Urine diseases.
See Also
- Get a free copy of the StockNews.com research report on Acer Therapeutics (ACER)
- Dave & Buster's Rebound Could Score for Investors
- Cal-Maine: Is it Time to Chase this Stock Higher?
- The Most Important Warren Buffett Stock for Investors: His Own
- Three Mid Caps Wall Street Sees Doubling Within 12 Months
- It's No Stretch: Lululemon Could Break Out of its Range
Receive News & Ratings for Acer Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acer Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
宏碁治療股份有限公司(納斯達克代碼:宏碁評級)-宏碁溫賴特的股票研究分析師在3月28日星期二發佈的一份研究報告中發佈了他們對宏碁治療公司2023年第二季度每股收益(EPS)的估計。HC Wainwright分析師V.Bernardino預測,這家生物製藥公司將公佈本季度每股收益為0.26美元。HC Wainwright對該股的評級為買入,目標價為12.00美元。對宏碁治療公司目前全年收益的普遍估計是每股0.23美元。
到達
宏基治療公司警報:
宏碁治療類股上漲1.3%
宏碁治療公司的股票週三開盤報0.76美元。宏基治療的52周低點為0.65美元,52周高點為4.56美元。該公司市值為1,601萬美元,本益比為-0.53倍,貝塔係數為0.65。該股的50日移動均線價格為1.86美元,200日移動均線價格為1.84美元。
宏基治療的機構性交易
一些機構投資者和對沖基金最近改變了他們在該業務中的頭寸。南塔哈拉資本管理有限責任公司在第四季度增持了宏碁治療公司76.0%的股份。Nantahala Capital Management LLC在上個季度增持了529,653股後,現在擁有這家生物製藥公司價值3,078,000美元的股票1,226,191股。諾特·David M Jr在第四季度收購了宏碁治療公司價值約351,000美元的新股。先鋒集團(Vanguard Group Inc.)在第一季度增持了宏碁治療公司55.5%的股份。先鋒集團(Vanguard Group Inc.)在上個季度增持了99,335股後,目前持有這家生物製藥公司278,215股股票,價值80.7萬美元。Meridian Wealth Management LLC在第四季度收購了宏碁治療公司價值約18萬美元的新股份。最後,復興科技有限責任公司在第二季度將其在宏碁治療公司的股份增加了216.8%。復興科技有限責任公司現在持有這家生物製藥公司6.97萬股票,價值8.8萬美元,在上個季度額外收購了4.77萬股票。27.96%的股票目前由對沖基金和其他機構投資者持有。
宏碁治療公司簡介
(獲取評級)
宏碁治療公司是一家制藥公司。從事醫療需求療法的獲取、開發和商業化。其產品線包括宏碁-001 Edsivo和宏碁-2820。Edsivo是一種治療血管Ehler-Danlos綜合徵的塞利洛爾。宏碁-001是用於治療尿素迴圈障礙和楓糖漿尿液疾病。
另請參閱
- 免費獲取StockNews.com關於宏碁治療(Acer)的研究報告
- Dave&Buster的反彈可能會為投資者帶來好處
- 加州緬因州:是時候追逐這只股票了嗎?
- 對投資者來說最重要的沃倫·巴菲特股票:他自己的股票
- 華爾街預計三隻中型股在12個月內翻一番
- 這是不可伸展的:lululemon可以突破它的範圍
接受《宏基治療日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對宏碁治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。